within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG06_Alemtuzumab;
model Alemtuzumab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AG06;

  annotation(Documentation(
    info ="<html><body><p>Alemtuzumab is a humanized monoclonal antibody directed against CD52, a protein present on the surface of mature lymphocytes, and is primarily used as an immunosuppressive agent in multiple sclerosis and previously in B-cell chronic lymphocytic leukemia (CLL). Its main purpose is to reduce relapse rates in relapsing forms of multiple sclerosis. It is an approved drug for use in several countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in patients with relapsing multiple sclerosis receiving intravenous alemtuzumab infusions.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Wagstaff, AJ (2003). Alemtuzumab. <i>Drugs</i> 63(12) 1229–1246. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363120-00003&quot;>10.2165/00003495-200363120-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12790693/&quot;>https://pubmed.ncbi.nlm.nih.gov/12790693</a></p></li><li><p>Admiraal, R, et al., &amp; Bredius, RGM (2019). Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. <i>Clinical pharmacokinetics</i> 58(12) 1609–1620. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00782-0&quot;>10.1007/s40262-019-00782-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31131436/&quot;>https://pubmed.ncbi.nlm.nih.gov/31131436</a></p></li><li><p>Loeff, FC, et al., &amp; Halkes, CJM (2019). Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. <i>Transplant immunology</i> 57 101209–None. DOI:<a href=&quot;https://doi.org/10.1016/j.trim.2019.06.001&quot;>10.1016/j.trim.2019.06.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31207283/&quot;>https://pubmed.ncbi.nlm.nih.gov/31207283</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Alemtuzumab;
